Patents Examined by Alexander R Pagano
  • Patent number: 10808001
    Abstract: A method for preparing a biflavone-cobalt complex includes using the amentoflavone as the ligand and the cobalt ion as the central ion, the amentoflavone-cobalt complex is obtained by reaction, and the structure of the complex is characterized by infrared spectroscopy, UV-vis absorption spectroscopy and high resolution mass spectrometry. Meanwhile, the antitumor and antioxidant activities of the amentoflavone-cobalt complex are studied in the present invention. MTT method shows that the amentoflavone-cobalt complex has better antitumor activity, and the antitumor activity thereof is stronger than that of the amentoflavone. Pyrogallol auto-oxidation method, ABTS method and FRAP method show that the antioxidan activity of the amentoflavone-cobalt complex is stronger than that of the amentoflavone itself. The formation of the flavonoid-cobalt complex enhances the antitumor and anti-oxidation activities of the amentoflavone, and is expected to be used in the development of drugs.
    Type: Grant
    Filed: February 13, 2018
    Date of Patent: October 20, 2020
    Assignee: NANJING FORESTRY UNIVERSITY
    Inventors: Guibin Wang, Li Xu, Shilong Yang, Fuliang Cao
  • Patent number: 10800888
    Abstract: The present invention relates to a compound having the following structure I: where Ar1, R, R1, E, m, n, x, y, p, and s are defined herein. The compound of the present invention is useful as an open time additive in waterborne coatings compositions, particularly waterborne paint compositions.
    Type: Grant
    Filed: June 25, 2018
    Date of Patent: October 13, 2020
    Assignees: Rohm and Haas Company, Dow Global Technologies, LLC
    Inventors: Edward D. Daugs, John J. Rabasco, Antony K. Van Dyk, Tianlan Zhang
  • Patent number: 10787464
    Abstract: The use of zinc ketoiminate complexes in the production of polyurethanes is described, wherein the zinc ketoiminate complexes are obtainable by reacting a zinc compound with certain ketimines.
    Type: Grant
    Filed: September 14, 2018
    Date of Patent: September 29, 2020
    Assignee: Evonik Operations GmbH
    Inventors: Michael Fiedel, Thomas Günther, Martin Glos, Michael Ferenz, Christian Eilbracht, Wilfried Knott, Stephan Schulz, Dennis Dittrich
  • Patent number: 10787474
    Abstract: A platinum organosiloxane complex is prepared by a process including 1) combining A) a platinous halide and B) a ketone, and thereafter 2) adding C) a polyorganosiloxane having, per molecule, 2 to 4 silicon bonded terminally unsaturated hydrocarbon groups having from 2 to 6 carbon. The platinum organosiloxane complex prepared by the process is useful as a hydrosilylation catalyst.
    Type: Grant
    Filed: July 18, 2018
    Date of Patent: September 29, 2020
    Assignee: Dow Silicones Corporation
    Inventors: Aswini Dash, Zhanjie Li, Andrew Millward, Ming-Shin Tzou
  • Patent number: 10781227
    Abstract: The present invention provides biologically active compounds and methods to obtain biologically active compounds that can be used as photosensitizers for diagnostic and therapeutic applications, particularly for PDT of cancer, infections and other hyperproliferative diseases, fluorescence diagnosis and PDT treatment of non-tumorous indications such as arthritis, inflammatory diseases, viral or bacterial infections, dermatological, ophthalmological or urological disorders. As the compounds exhibit also toxicity against targets (tumor cells, bacteria, inflammation-related cells) without light these biologically active compounds may also be used for the light-independent treatment of such indications. Preferred embodiments of the present invention consist of methods to synthesize metal or half-metal complex structures incorporating one or more substituted 2,3,5,6-tetrafluorophenyl-dipyrromethene (2,3,5,6-tetrafluorophenyldipyrrin) units.
    Type: Grant
    Filed: February 4, 2019
    Date of Patent: September 22, 2020
    Assignee: Biolitec Unternehmensbeteiligungs II AG
    Inventors: Claudia S. Gutsche, Arno Wiehe, Benjamin F. Hohlfeld, Burkhard Gitter, Volker Albrecht
  • Patent number: 10780305
    Abstract: Novel organosiloxane compounds are disclosed that are useful in firefighting foams. Methods of making and using the organosiloxane compounds and foams are also described.
    Type: Grant
    Filed: March 16, 2017
    Date of Patent: September 22, 2020
    Assignee: Tyco Fire Products LP
    Inventors: Yuan Xie, Amy J. Wirth, Philip J. Karjala
  • Patent number: 10774050
    Abstract: The present disclosure provides substituted pyrimidine compounds of Formula (I), and the pharmaceutically acceptable salts, prodrugs, and solvates thereof, wherein A1, X, A2, W1, W2, W3, E, Z, and R4 are defined as set forth in the specification. The present disclosure is also directed to the use of compounds of Formula (I) to treat a disorder responsive to the blockade of sodium channels. Compounds of the present disclosure are especially useful for treating pain.
    Type: Grant
    Filed: June 1, 2018
    Date of Patent: September 15, 2020
    Assignee: Purdue Pharma, L.P.
    Inventors: Chiyou Ni, Laykea Tafesse, Jiangchao Yao, Mark A. Youngman, Minnie Park, Bin Shao
  • Patent number: 10774073
    Abstract: The invention relates to inhibitors of dihydrofolate reductase and pharmaceutical preparations thereof. The invention further relates to methods of treatment of parasitic infections, such as T. gondii, T. cruzi, P. falciparum, T. brucei, or L. major infections, using the novel inhibitors of the invention.
    Type: Grant
    Filed: February 2, 2017
    Date of Patent: September 15, 2020
    Assignee: Vyera Pharmaceuticals, LLC
    Inventors: Stephen B. Thomas, Allen T. Hopper, Matthew Welsch
  • Patent number: 10772872
    Abstract: Novel, antimitotic heteroaryl amides and pharmaceutically acceptable salts of Formula I where Ar, R5, R6, R8, R9, R11, X1, and X2 are as defined herein, as compounds for treatment and prevention of cancer and proliferative diseases and disorders.
    Type: Grant
    Filed: June 29, 2018
    Date of Patent: September 15, 2020
    Assignee: Frost Biologic, Inc.
    Inventor: Adam Siddiqui-Jain
  • Patent number: 10766884
    Abstract: This invention relates to compounds of Formula (I) or a pharmaceutically acceptable salt thereof, in which R-groups R1 to R23, A, Q, U, V, W, X, Y, Z, n, p and q are as defined herein, to pharmaceutical compositions comprising such compounds and salts, and to methods of using such compounds, salts and compositions for the treatment of abnormal cell growth, including cancer, in a subject.
    Type: Grant
    Filed: April 23, 2019
    Date of Patent: September 8, 2020
    Assignee: Pfizer Inc.
    Inventors: Ping Chen, Sujin Cho-Schultz, Judith Gail Deal, Gary Michael Gallego, Mehran Jalaie, Robert Steven Kania, Sajiv Krishnan Nair, Sacha Ninkovic, Suvi Tuula Marjukka Orr, Cynthia Louise Palmer
  • Patent number: 10765624
    Abstract: Provided are compounds of Formula I: or a pharmaceutically acceptable salt thereof, wherein R1, R2, R3, R4, R5, R6, R7, R8, R9, X and m are as defined herein. Also provided is a pharmaceutically acceptable composition comprising a compound of Formula I, or a pharmaceutically acceptable salt thereof. Also provided are methods of using a compound of Formula I, or a pharmaceutically acceptable salt thereof.
    Type: Grant
    Filed: March 13, 2019
    Date of Patent: September 8, 2020
    Assignee: CYTOKINETICS, INC.
    Inventors: Zhe Yang, Alex R. Muci, Jeffrey Warrington, Gustave Bergnes, Bradley P. Morgan, Chihyuan Chuang, Antonio Romero, Scott Collibee, Xiangping Qian, Pu-Ping Lu
  • Patent number: 10765681
    Abstract: The present disclosure provides compounds of Formulas (I?) and (I), and pharmaceutically acceptable salts thereof. The compounds described herein may be useful in treating and/or preventing proliferative diseases (e.g., cancer). Also provided in the present disclosure are pharmaceutical compositions, kits, and uses thereof for treating proliferative diseases.
    Type: Grant
    Filed: February 3, 2017
    Date of Patent: September 8, 2020
    Assignees: Academia Sinica, National Taiwan University
    Inventors: Chi-Huey Wong, Pan-Chyr Yang, Jim-Min Fang, Szu-Hua Pan, Ting-Jen R. Cheng, Ling-Wei Li
  • Patent number: 10766881
    Abstract: Provided herein are compounds of the general Formula I: and stereoisomers and pharmaceutically acceptable salts or solvates thereof, in which X, R1, R2, R3, Ring A and z have the meanings given in the specification, which are inhibitors of FGFR1, FGFR2, FGFR3 and/or FGFR4 and are useful in the treatment and prevention of diseases which can be treated with an FGFR inhibitor, including diseases or disorders mediated by FGFR1, FGFR2, FGFR3 and/or FGFR4.
    Type: Grant
    Filed: February 14, 2019
    Date of Patent: September 8, 2020
    Assignee: Array Biopharma Inc.
    Inventors: Steven W. Andrews, James F. Blake, Adam Cook, Indrani W. Gunawardana, Kevin W. Hunt, Andrew T. Metcalf, David Moreno, Li Ren, Tony P. Tang
  • Patent number: 10758538
    Abstract: The present subject matter relates to a compound represented by the general formula (I) or (I?) or a pharmacologically acceptable salt thereof; pharmaceutical compositions containing at least one of these compounds; methods of making at least one of these compounds; methods of using at least one of these compounds for treating and/or preventing various cancers and/or proliferation disorders; methods of using at least one of these compounds for monitoring the effectiveness of an anticancer therapy against various cancers. In one embodiment, the subject matter relates to compounds that bind with a level of specificity to heat shock protein 70 (Hsp70). In another embodiment, the subject matter relates to compounds that bind with a level of specificity to inhibit both heat shock protein 70 (Hsp70) and heat shock cognate protein 70 (Hsc70).
    Type: Grant
    Filed: July 17, 2018
    Date of Patent: September 1, 2020
    Assignee: Memorial Sloan-Kettering Cancer Center
    Inventors: Gabriela Chiosis, Tony Taldone, Anna Rodina, Pallav Patel, Yanlong Kang
  • Patent number: 10751310
    Abstract: Various embodiments of this invention are directed to pharmaceutical compositions and methods for treating disease. The compositions of such embodiments include dicarboxylic acid compounds containing electron withdrawing groups, alkyl esters of dicarboxylic acids containing electron withdrawing groups, or compounds of Formulae I to X. The methods of various embodiments include administering an effective amount of any of these pharmaceutical compositions to a patient in need of treatment.
    Type: Grant
    Filed: March 2, 2017
    Date of Patent: August 25, 2020
    Assignee: University of Pittsburgh—Of the Commonwealth System of Higher Education
    Inventors: Bruce A. Freeman, Francisco J. Schopfer
  • Patent number: 10745413
    Abstract: The present disclosure provides methods for synthesizing cantharidin and cantharidin derivatives.
    Type: Grant
    Filed: December 17, 2015
    Date of Patent: August 18, 2020
    Assignee: Verrica Pharmaceuticals, Inc.
    Inventors: Matthew Davidson, Steven R. Schow
  • Patent number: 10745337
    Abstract: In an embodiment a method of purifying acetone, comprises directing a feed stream comprising greater than or equal to 97 wt % of acetone and 100 to 1,000 ppm of methanol to a separation column, both based on a total weight of the feed stream; separating the feed stream in the separation column that is operating at a pressure greater than or equal to 1 bar into an overhead stream and a purified acetone stream comprising less than or equal to 50 ppm of methanol based on a total weight of the purified acetone stream; and directing at least 80 wt % of the overhead stream into the separation column as a reconstituted stream and purging 1 to 20 wt % of the overhead stream as a purge stream.
    Type: Grant
    Filed: October 3, 2018
    Date of Patent: August 18, 2020
    Assignee: SABIC GLOBAL TECHNOLOGIES B.V.
    Inventors: Surya Prakasa Rao Daliparthi, Nathalie Gonzalez Vidal, Paulus Johannes Maria Eijsbouts
  • Patent number: 10738056
    Abstract: The present invention relates to pyrazolopyrimidinone compounds. The present invention also relates to pharmaceutical compositions containing these compounds and methods of treating autoimmune, inflammatory, and neurodegenerative diseases by administering these compounds and pharmaceutical compositions to subjects in need thereof. The present invention also relates to the use of such compounds for research or other non-therapeutic purposes.
    Type: Grant
    Filed: September 14, 2018
    Date of Patent: August 11, 2020
    Assignee: Aduro BioTech Inc.
    Inventors: Chudi Obioma Ndubaku, George Edwin Katibah, Tucker Curran Roberts, Leonard Sung, Stephane Ciblat, Franck Raeppel, Vu Linh Ly, Yeeman K. Ramtohul, Taras Rybak, Mariam Zaky, Laura Gillard, Hossein Ismaili
  • Patent number: 10738067
    Abstract: The present invention provides various compositions, including compounds of Formula (I) or (Ia), or a species thereof, and pharmaceutically acceptable salts, solvates (e.g., hydrates), stereoisomer, tautomers, isotopic and other specified forms thereof. Also provided are methods (or uses) and kits involving the compounds or pharmaceutically acceptable compositions containing them for treating or preventing a disease (e.g., a proliferative disease such as cancer) in a subject. Administration of a compound or pharmaceutical composition described herein is expected to inhibit cyclin-dependent kinase 7 (CDK7), and thereby, induce apoptosis in tumor cells in the subject.
    Type: Grant
    Filed: February 11, 2020
    Date of Patent: August 11, 2020
    Assignee: Syros Pharmaceuticals, Inc.
    Inventors: Jason J. Marineau, Michael Bradley, Claudio Edmundo Chuaqui, Stephane Ciblat, Anzhelika Kabro
  • Patent number: 10738040
    Abstract: The present disclosure features disclosed compounds which can increase cystic fibrosis transmembrane conductance regulator (CFTR) activity as measured in human bronchial epithelial (hBE) cells. The present disclosure also features methods of treating a condition associated with decreased CFTR activity or a condition associated with a dysfunction of proteostasis comprising administering to a subject an effective amount of a disclosed compound.
    Type: Grant
    Filed: November 14, 2018
    Date of Patent: August 11, 2020
    Assignee: Proteostasis Therapeutics, Inc.
    Inventors: Cecilia M. Bastos, Benito Munoz, Bradley Tait